# Michael Huang

> Michael Huang is a Series C investor at Taiwania Capital Management Corporation backing Biotechnology. See 12 investments, check sizes, portfolio. Updated…

- Type: Angel Investor
- Fund: [Taiwania Capital Management Corporation](https://shizune.co/investors/profile/taiwania-capital)
- Total investments: 12
- Last investment: Jan 2026
- Lead investor: 83%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/michael-huang-24b92320a

Michael Huang is a Series C investor at Taiwania Capital Management Corporation focused on Biotechnology and Medical. Michael Huang

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 58% |
| Medical | 5 | 42% |
| Health Care | 5 | 42% |
| Therapeutics | 4 | 33% |
| Medical Device | 4 | 33% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 25% |
| Series B | 2 | 17% |
| Series E | 2 | 17% |
| Series A | 1 | 8% |
| Series D | 1 | 8% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 50% |
| Taiwan | 1 | 8% |
| Switzerland | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Rakuten Medical | Rakuten Medical is a biotechnology company developing investigational cancer therapies based on its proprietary Alluminox platform. This platform integrates a drug, a device, and other components to deliver photoimmunotherapy, a treatment that combines a light-activated dye with a targeting agent to selectively destroy cancer cells. Thecompany's lead asset, ASP-1929, is an antibody-dye conjugate currently approved in Japan for treating unresectable locally advanced or recurrent head and neck cancer. Rakuten Medical is conducting global clinical trials to evaluate the safety and efficacy of its therapies in combination with other treatments. The company also offers an Expanded Access Program to provide investigational products to patients with serious or life-threatening diseases who lack other treatment options. Rakuten Medical operates in multiple countries and focuses on developing new cancer treatments based on its Alluminox™ platform. | $111.5M | Series F | Jan 07, 2026 |  |
| Health2Sync | Health2Sync takes legacy medical devices and transforms your smartphone into a smart health monitoring machine; connecting users, loved ones, and clinicians. Our first product comes in the form of an app and accessory for smart blood glucose monitoring. | $20M | Series C | Mar 05, 2025 |  |
| Flat Medical | A medtech startup focusing on safety issues in clinical practices, delivering safe and affordable medical environment to everyone |  | Series C | Oct 02, 2023 |  |
| Nanolive | Nanolive SA was incorporated in November 2013 at the EPFL Innovation Park in Lausanne, Switzerland, by Dr. Yann Cotte (CEO) and Dr. Fatih Toy (scientific advisor), following the completion of their respective PhD theses at the EPFL Microsystems laboratory of Prof. Christian Depeursinge (Head of Scientific Advisory Board). | $2.2M | Series C | Sep 20, 2022 |  |
| Regenacy Pharmaceuticals | Regenacy Pharmaceuticals they give services to treat diabetic and other peripheral neuropathies. | $9.3M | Series B | Aug 15, 2022 |  |
| Nanolive | Nanolive SA was incorporated in November 2013 at the EPFL Innovation Park in Lausanne, Switzerland, by Dr. Yann Cotte (CEO) and Dr. Fatih Toy (scientific advisor), following the completion of their respective PhD theses at the EPFL Microsystems laboratory of Prof. Christian Depeursinge (Head of Scientific Advisory Board). | $20M | Series C | Apr 04, 2022 |  |
| Windgap Medical | WindGap Medical is a biotech company that manufactures medical devices used to treat patients with severe allergies. The company develops auto-injectors that are filled with heat-stable epinephrine that enable physicians to inject it into a patient suffering from anaphylaxis due to an acute allergy attack.The company was established in 2011 andis headquartered in Somerville, Massachusetts. | $39.2M | Series B | Sep 10, 2021 |  |
| Viracta Therapeutics | Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application ofthis inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. | $40M | Series E | Nov 30, 2020 |  |
| Fractyl Health | Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease. | $55M | Series E | Aug 06, 2020 |  |
| Fractyl Health | Fractyl Health develops innovative medical device solutions for the treatment of chronic diseases. The growing product pipeline leverages our minimally invasive procedural therapy, Revita DMR (duodenal mucosal resurfacing), which is designed to rejuvenate the lining of the duodenum and improve patient health. They envision a world with bettersolutions to chronic diseases through the use of less invasive, device-based therapies that will lessen the burden on patients, physicians, and payers.Fractyl Health aims to bring curative therapies to the large populations of patients with metabolic disease. | $55M | Series E | Aug 06, 2020 |  |

10 of 12 investments shown.

## Co-investors
- [Cobro Ventures](https://shizune.co/investors/profile/cobro-ventures) — VC Fund, 3 deals together
- [3E Bioventures](https://shizune.co/investors/profile/3e-bioventures) — VC Fund, 2 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 2 deals together
- [CDIB Ventures](https://shizune.co/investors/profile/cdib-ventures-2) — VC Fund, 2 deals together
- [Domain Associates](https://shizune.co/investors/profile/domain-associates) — VC Fund, 2 deals together
- [Emergent Medical Partners](https://shizune.co/investors/profile/emergent-medical-partners) — VC Fund, 2 deals together

## About Taiwania Capital Management Corporation

VC Fund · Taipei, Taiwan

Taiwania Capital is a venture capital firm that establishes partnership with worldwide companies and to boost Taiwan’s economic growth.

4 contacts available at Taiwania Capital Management Corporation.

| Name | Title | Profile |
| --- | --- | --- |
| Cheng Wu | General Partner | https://shizune.co/investors/profile/cheng-wu |
| David Weng | CEO | https://shizune.co/investors/profile/david-weng-fe24 |
| Michael Huang | Managing Partner | https://shizune.co/investors/profile/michael-huang-59bf |
| Michael Shieh | Entrepreneur In Residence | https://shizune.co/investors/profile/michael-shieh-va |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Michael Huang invest in?

Michael Huang invests primarily in Biotechnology, Medical and Health Care startups, most often at Series C and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michael Huang last invest?

The most recent investment recorded for Michael Huang closed in Jan 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co